Agios Pharmaceuticals (AGIO) Could Be 11% Undervalued Following Mixed Sickle Cell Updates
Agios Pharmaceuticals (AGIO) shares are reacting to mixed sickle cell disease updates, as the company ends development of tebapivat for this indication while securing FDA Priority Review for its mitapivat supplemental application.
See our latest analysis for Agios Pharmaceuticals.
At a share price of $36.36, Agios Pharmaceuticals has seen short term momentum cool, with a 7 day share price return down 8.21% and a 30 day share price return down 4.06%. This comes even as its 90 day share price return of 48.83% and 3 year total shareholder return of 36.79% point to a stock that has previously rewarded patience more than quick trades.
If you are reassessing Agios Pharmaceuticals after these sickle cell updates and want to see what else is moving, this could be a good moment to look at 40 healthcare AI stocks.
Agios Pharmaceuticals is working to build a focused rare disease business, but after the latest sickle cell news and share pullback, the key issue now is whether the current price already reflects that potential or still leaves room for upside.
Most Popular Narrative: 11% Undervalued
Agios Pharmaceuticals is trading at $36.36 compared with a narrative fair value estimate of $40.88, which puts the focus firmly on what needs to go right to close that gap.
Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is set to significantly expand Agios' addressable market, driven by the high rate of disease diagnosis through newborn screening and well-defined patient populations, which should lift revenue growth in coming years.
Curious what kind of revenue ramp, margin shift, and future earnings multiple underpin that fair value tag for Agios Pharmaceuticals, and how tightly it all leans on PYRUKYND.
Result: Fair Value of $40.88 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Agios Pharmaceuticals story could change quickly if PYRUKYND faces tighter safety labeling that slows uptake, or if international partnerships deliver meaningfully slower revenue contribution than expected.
Find out about the key risks to this Agios Pharmaceuticals narrative.
Another View on Agios Pharmaceuticals: Valuation Through Sales Multiples
The fair value narrative for Agios Pharmaceuticals points to an 11% discount, but its current P/S of 32.7x sits far above the US Biotechs industry at 10.8x and peers at 3x. With a fair ratio of 0x, this suggests the market could shift sharply if sentiment cools.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed signals in this Agios Pharmaceuticals story, you may want to review the numbers yourself and then weigh both sides with the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Agios Pharmaceuticals?
Do not stop with Agios Pharmaceuticals. Broaden your watchlist now, because some of the most interesting opportunities often sit just outside the stocks already on your radar.
- Spot potential turnaround stories early by reviewing the 20 elite penny stocks with strong financials that combine smaller market sizes with stronger financial profiles than many investors expect.
- Strengthen the core of your portfolio by scanning the solid balance sheet and fundamentals stocks screener (49 results) so you can focus on businesses backed by healthier financial foundations.
- Get ahead of the crowd by checking the screener containing 19 high quality undiscovered gems before others start paying attention to their fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com